



Unifying the care experience

APPENDIX 4E  
PRELIMINARY FINAL  
REPORT  
YEAR ENDED  
31 DECEMBER 2023

For personal use only



For personal use

# Appendix 4E

## Preliminary Final Report

### Oneview Healthcare PLC

ABN 610 611 768

#### 1. Company Details

Name of Entity

**Oneview Healthcare PLC**

ABN or equivalent  
company reference

**610 611 768**

Financial year ended  
(current period)

**31 December 2023**

Financial year ended  
(previous period)

**31 December 2022**

#### 2. Results for announcement to the market

	Up/down	% change	31 December 2023 €'000	31 December 2022 €'000
Recurring revenue from ordinary activities	Up	7%	6,600	6,185
Total revenue from ordinary activities	Up	5%	9,397	8,921
(Loss) from ordinary activities after tax attributable to members (including significant items)	Down	18%	(8,935)	(10,869)
(Loss) from ordinary activities after tax attributable to members (excluding significant items *)	Down	20%	(6,252)	(7,815)

\* Significant items incurred include FX and non-cash share based payments.

#### 3. Net Tangible Assets Per Security

	31 December 2023 €	31 December 2022 €
Net Tangible Assets Per Security	0.013	0.004

Net tangible assets are defined as the net assets of Oneview Healthcare PLC less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

#### **4. Commentary on Results**

The principal activity of the Group is the development and sale of software for the healthcare sector and the provision of related consultancy services.

The directors report that revenue for the year from continuing operations amounted to €9,397,373 (2022: €8,921,499), an increase of 5%. Recurring revenue for the year amounted to €6,600,035 (2022: €6,185,160), an increase of 7% and continues to grow as the company deploys across its customer base.

As at 31 December 2023, the Oneview solution was live in 10,151 beds with a further 5,670 beds contracted but not yet installed.

#### **5. Dividends**

The Company has not declared, and does not propose to pay, any dividends for the year ended 31 December 2023 (31 December 2022: Nil). There are no dividend or dividend reinvestment plans in operation.

#### **6. Details of entities over which control has been gained or lost during the period**

There are no entities over which control has been gained or lost in the period.

#### **7. Associates and joint venture entities**

There are no associate or joint venture entities.

#### **8. Audit status**

This Appendix 4E and the included financial information are based on financial statements which have not been audited, but are in the process of being audited.

#### **9. Foreign entity accounting standards**

The Financial Statements contained within the Preliminary Final Report are measured and recognised in accordance with International Financial Reporting Standards, as adopted by the European Union.

#### **10. Financial Report**

The following financial report included in this Appendix 4E does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and operating, financial and investing activities of the consolidated entity as the full annual financial report. This financial report should be read in conjunction with any public announcements made by Oneview Healthcare PLC in accordance with the continuous disclosure obligations of the ASX Listing Rules.

The accounting policies are the same as those applied in the most recent interim financial report and the previous annual report.

## Consolidated Statement of Total Comprehensive Income for the year ended 31 December 2023

		2023 Unaudited	2022 Audited
	Note	€	€
<b>Revenue</b> - continuing operations	2	<b>9,397,373</b>	8,921,499
Cost of sales		<b>(3,232,587)</b>	(3,575,857)
<b>Gross profit</b>		<b>6,164,786</b>	5,345,642
Other income	3	-	1,360,637
Sales and marketing expenses		<b>(3,127,283)</b>	(3,918,579)
Product development and delivery expenses		<b>(8,341,433)</b>	(10,070,026)
General and administrative expenses		<b>(3,069,122)</b>	(3,543,075)
<b>Operating loss</b>		<b>(8,373,052)</b>	(10,825,401)
Finance charges		<b>(517,038)</b>	(162,459)
Finance income		<b>5,254</b>	63,180
<b>Loss before tax</b>		<b>(8,884,836)</b>	(10,924,680)
Income tax		<b>(49,735)</b>	55,221
<b>Loss for the year</b>		<b>(8,934,571)</b>	(10,869,459)
<b>Attributable to ordinary shareholders</b>		<b>(8,934,571)</b>	(10,869,459)
<i>Loss per share</i>			
Basic	4	<b>(0.02)</b>	(0.02)
Diluted	4	<b>(0.02)</b>	(0.02)
<b>Other comprehensive gain/(loss)</b>			
<i>Items that will or may be reclassified to profit or loss:</i>			
Foreign currency translation differences on foreign operations (no tax impact)		<b>158,081</b>	(80,260)
Other comprehensive loss, net of tax		<b>158,081</b>	(80,260)
<b>Total comprehensive loss for the year</b>		<b>(8,776,490)</b>	(10,949,719)

The total comprehensive loss for the year is entirely attributable to equity holders of the Group.



## Consolidated Statement of Financial Position as at 31 December 2023

		2023 Unaudited	2022 Audited
	Note	€	€
<b>Non-current assets</b>			
Intangible assets	5	491,386	264,877
Property, plant and equipment	6	1,037,034	613,779
Research and development tax credit	7	461,061	639,639
<b>Total non-current assets</b>		<b>1,989,481</b>	1,518,295
<b>Current assets</b>			
Inventories		2,240,906	1,227,691
Trade and other receivables	7	5,708,046	3,342,163
Contract assets		430,906	240,035
Current income tax receivable		-	16,025
Cash and cash equivalents		11,548,825	6,409,936
<b>Total current assets</b>		<b>19,928,683</b>	11,235,850
<b>Total assets</b>		<b>21,918,164</b>	12,754,145
<b>Equity</b>			
Issued share capital	10	671,482	534,990
Share premium	10	134,082,384	120,369,325
Treasury reserve		(2,586)	(2,586)
Other undenominated capital		4,200	4,200
Translation reserve		172,075	13,994
Reorganisation reserve		(1,351,842)	(1,351,842)
Share based payments reserve		7,217,895	6,446,943
Retained earnings		(131,653,947)	(123,758,477)
<b>Total equity</b>		<b>9,139,661</b>	2,256,547
<b>Non-current liabilities</b>			
Trade and other payables	9	247,225	2,789,637
Lease liabilities		782,456	370,732
Deferred income		12,058	20,295
<b>Total non-current liabilities</b>		<b>1,041,739</b>	3,180,664
<b>Current liabilities</b>			
Trade and other payables	8	11,570,211	7,144,655
Lease liabilities		152,866	172,279
Current income tax liabilities		13,687	-
<b>Total current liabilities</b>		<b>11,736,764</b>	7,316,934
<b>Total liabilities</b>		<b>12,778,503</b>	10,497,598
<b>Total equity and liabilities</b>		<b>21,918,164</b>	12,754,145

## Consolidated Statement of Cash Flows

for the year ended 31 December 2023

		2023	2022
		Unaudited	Audited
	Note	€	€
<b>Cash flows from operating activities</b>			
Receipts from customers		9,721,389	8,838,970
Legal claim settlement proceeds		-	1,360,637
Payments to employees and suppliers		(16,812,803)	(19,609,240)
Finance charges paid		(127,455)	(104,932)
Interest received		5,254	570
Research and development tax credit received		-	621,561
Income tax paid		(50,173)	(17,647)
<b>Net cash used in operating activities</b>	11	<b>(7,263,788)</b>	<b>(8,910,081)</b>
<b>Cash flows from investing activities</b>			
Purchase of property, plant and equipment	6	(118,444)	(44,518)
Acquisition of intangible assets	5	(402,933)	-
<b>Net cash used in investing activities</b>		<b>(521,377)</b>	<b>(44,518)</b>
<b>Cash flows from financing activities</b>			
Proceeds from issue of shares		13,839,783	309,458
Transaction costs		(548,527)	(91,640)
Repayment of lease liabilities		(253,778)	(317,925)
<b>Net cash provided by/(used in) financing activities</b>		<b>13,037,478</b>	<b>(100,107)</b>
Net increase/(decrease) in cash held		5,252,313	(9,054,706)
Foreign exchange impact on cash and cash equivalents		(113,424)	288,657
Cash and cash equivalents at beginning of financial year		6,409,936	15,175,985
<b>Cash and cash equivalents at end of financial year</b>		<b>11,548,825</b>	<b>6,409,936</b>

For personal use only

## Consolidated Statement of Changes in Equity

as at 31 December 2023

	Share capital	Share premium	Treasury reserve	Other undenominated capital	Reorganisation reserve	Share based payments reserve	Translation reserve	Retained earnings	Total equity
	€	€	€	€	€	€	€	€	€
<b>As at 1 January 2022</b>	<b>518,477</b>	<b>120,071,867</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>4,344,439</b>	<b>94,254</b>	<b>(113,778,692)</b>	<b>9,900,117</b>
Loss for the year	-	-	-	-	-	-	-	(10,869,459)	(10,869,459)
Foreign currency translation	-	-	-	-	-	-	(80,260)	-	(80,260)
<b>Total comprehensive loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(80,260)</b>	<b>(10,869,459)</b>	<b>(10,949,719)</b>
<i>Transactions with shareholders</i>									
Exercise of share options	12,000	297,458	-	-	-	(68,758)	-	68,758	309,458
Share based compensation to employees	-	-	-	-	-	2,996,691	-	-	2,996,691
Vesting of restricted share unit awards	4,513	-	-	-	-	(609,773)	-	605,260	-
Transfer to retained earnings in respect of expired restricted share unit awards	-	-	-	-	-	(215,135)	-	215,135	-
Transfer to retained earnings in respect of expired options	-	-	-	-	-	(521)	-	521	-
<b>As at 31 December 2022</b>	<b>534,990</b>	<b>120,369,325</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>6,446,943</b>	<b>13,994</b>	<b>(123,758,477)</b>	<b>2,256,547</b>



## Consolidated Statement of Changes in Equity (continued)

as at 31 December 2022

	Share capital	Share premium	Treasury reserve	Other undenominated capital	Reorganisation reserve	Share based payments reserve	Translation reserve	Retained earnings	Total equity
	€	€	€	€	€	€	€	€	€
<b>As at 1 January 2023</b>	<b>534,990</b>	<b>120,369,325</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>6,446,943</b>	<b>13,994</b>	<b>(123,758,477)</b>	<b>2,256,547</b>
Loss for the year	-	-	-	-	-	-	-	(8,934,571)	(8,934,571)
Foreign currency translation	-	-	-	-	-	-	158,081	-	158,081
<b>Total comprehensive loss</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>158,081</b>	<b>(8,934,571)</b>	<b>(8,776,490)</b>
<i>Transactions with shareholders</i>									
Issue of ordinary shares	126,724	13,713,059	-	-	-	-	-	(548,527)	13,291,256
Issue of ordinary shares as consideration for services	2,083	-	-	-	-	(224,027)	-	221,944	-
Share based compensation to employees	-	-	-	-	-	2,038,852	-	-	2,038,852
Share based compensation to non-employees	-	-	-	-	-	329,496	-	-	329,496
Vesting of restricted share unit awards	7,685	-	-	-	-	(1,072,874)	-	1,065,189	-
Transfer to retained earnings in respect of expired restricted share unit awards	-	-	-	-	-	(299,740)	-	299,740	-
Transfer to retained earnings in respect of expired options	-	-	-	-	-	(755)	-	755	-
<b>As at 31 December 2023</b>	<b>671,482</b>	<b>134,082,384</b>	<b>(2,586)</b>	<b>4,200</b>	<b>(1,351,842)</b>	<b>7,217,895</b>	<b>172,075</b>	<b>(131,653,947)</b>	<b>9,139,661</b>

## **1. Statement of Significant Accounting Policies**

### **Statement of compliance**

This report is not a set of statutory financial statements and does not include all the information required for a complete set of financial statements, prepared in accordance with IFRS as adopted by the European Union. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since 31 December 2022. They should be read in conjunction with the statutory consolidated financial statements of the Group, which were prepared in accordance with IFRS as adopted by the European Union, as at and for the year ended 31 December 2022 and also in conjunction with any public announcements made by Oneview Healthcare PLC during the year.

### **Going Concern**

The Group's financial statements have been prepared and presented on a going concern basis.

This report adopts the going concern basis of accounting, which contemplates the realisation of assets and the discharge of liabilities and commitments in the ordinary course of business.

During the year, the Company successfully conducted a Placement and Securities Purchase Plan (SPP) which raised A\$22.8 million (€13.8 million) before costs. The Company has an extensive sales pipeline, of which several opportunities are expected to be contracted in the coming months. Accordingly, the Directors believe the business has adequate levels of working capital to fund the Group's strategic goals. They believe, therefore, that the Group continues to be a going concern and that it will be able to pay its debts as and when they fall due, for a period of at least 12 months from the date of this report.

On this basis, the Directors believe that the going concern basis of presentation is appropriate. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Group not have the ability to continue as a going concern. If for any reason the Group is unable to continue as a going concern, it would impact on the Group's ability to realise assets at their recognised values and to extinguish liabilities in the normal course of business at the amounts stated in the consolidated financial statements.

### **Use of estimates and judgments**

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected. In preparing this financial report, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation and uncertainty were the same as those that apply to the consolidated financial statements for the year ended 31 December 2022.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**2. Revenue**

**Revenue by type**

<b>Recurring revenue:</b>	<b>2023</b>	2022
	<b>Unaudited</b>	Audited
	€	€
Software usage and content	<b>4,261,096</b>	3,978,661
Support income	<b>2,194,692</b>	2,055,044
Licence fee	<b>144,247</b>	151,455
	<b>6,600,035</b>	6,185,160
<b>Non-recurring revenue:</b>		
Hardware	<b>1,966,050</b>	1,701,684
Services income	<b>831,288</b>	1,034,655
	<b>2,797,338</b>	2,736,339
<b>Total revenue</b>	<b>9,397,373</b>	8,921,499

<b>Revenue attributable to geographic region:</b>	<b>2023</b>	2022
	<b>Unaudited</b>	Audited
	€	€
Ireland	<b>42,684</b>	4,200
United States	<b>6,375,059</b>	5,679,550
Australia	<b>2,366,402</b>	2,864,910
Asia	<b>545,327</b>	279,128
Middle East and North Africa	<b>67,901</b>	93,711
<b>Total revenue</b>	<b>9,397,373</b>	8,921,499

**3. Other income**

There was no other income in 2023. The other income in the prior year related to a commercial settlement agreed with aged care operator Regis Aged Care Pty Ltd in relation to the claim launched by the Company for breach of the Collaboration Agreement between the parties without admission of liability of either party. A settlement of A\$2 million (€1.36 million) was agreed and was received by the Company in May 2022. Legal fees of €0.07 million associated with the claim were incurred and paid during the prior year and are reflected in professional and legal fees within general and administrative costs.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**4. Earnings per share**

	<b>2023</b> <b>Unaudited</b> €	2022 Audited €
<b>Basic earnings per share</b>		
Loss attributable to ordinary shareholders	<b>(8,934,571)</b>	(10,869,459)
Weighted average number of ordinary shares outstanding (i)	<b>588,668,829</b>	522,319,679
<b>Basic loss per share</b>	<b>(0.02)</b>	(0.02)
	<b>2023</b> No.	2022 No.
<b>(i) Weighted-average number of ordinary shares (basic)</b>		
Issued ordinary shares at 1 January	<b>534,990,444</b>	518,477,053
Effect of shares issued	<b>53,678,385</b>	3,842,626
Weighted average number of ordinary shares at 31 December	<b>588,668,829</b>	522,319,679

Basic loss per share is calculated by dividing the loss for the year after taxation attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year.

	<b>2023</b> <b>Unaudited</b> €	2022 Audited €
<b>Diluted earnings per share</b>		
Loss attributable to ordinary shareholders	<b>(8,934,571)</b>	(10,869,459)
Weighted average number of ordinary shares outstanding (i)	<b>588,668,829</b>	522,319,679
<b>Diluted loss per share</b>	<b>(0.02)</b>	(0.02)

For personal use only

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**4. Earnings per share (continued)**

	<b>2023</b>	2022
	<b>No.</b>	No.
<b>(ii) Weighted-average number of ordinary shares (diluted)</b>		
Issued ordinary shares at 1 January	<b>534,990,444</b>	518,477,053
Effect of shares issued	<b>53,678,385</b>	3,842,626
Weighted average number of ordinary shares at 31 December	<b><u>588,668,829</u></b>	<u>522,319,679</u>

The calculation of diluted earnings per share has been based on the loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding after adjustments for the effects of all dilutive ordinary shares. Potential ordinary shares are treated as dilutive when, and only when, their conversion to ordinary shares would decrease EPS or increase the loss per share from continuing operations. As the Group is loss making there is no difference between the basic and diluted earnings per share. The number of ordinary shares, including potentially dilutive shares is 703,658,850 (2022: 567,057,257). The weighted average number of ordinary shares, including potentially dilutive shares, is 640,806,485 (2022: 562,689,187).

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**5. Intangible assets**

	<b>Software</b> €	<b>Development costs</b> €	<b>Total</b> €
<b>Cost</b>			
At 1 January 2022	215,685	5,213,747	5,429,432
Foreign exchange translation differences	5,602	-	5,602
<b>At 31 December 2022</b>	<b>221,287</b>	<b>5,213,747</b>	<b>5,435,034</b>
At 1 January 2023	221,287	5,213,747	5,435,034
Additions	18,006	384,927	402,933
<b>At 31 December 2023</b>	<b>239,293</b>	<b>5,598,674</b>	<b>5,837,967</b>
<b>Accumulated amortisation and impairment losses</b>			
At 1 January 2022	215,685	4,734,980	4,950,665
Amortisation	-	213,890	213,890
Foreign exchange translation differences	5,602	-	5,602
<b>At 31 December 2022</b>	<b>221,287</b>	<b>4,948,870</b>	<b>5,170,157</b>
At 1 January 2023	221,287	4,948,870	5,170,157
Amortisation	-	176,424	176,424
<b>At 31 December 2023</b>	<b>221,287</b>	<b>5,125,294</b>	<b>5,346,581</b>
<b>Carrying amount</b>			
At 1 January 2022	-	478,767	478,767
At 31 December 2022	-	264,877	264,877
<b>At 31 December 2023</b>	<b>18,006</b>	<b>473,380</b>	<b>491,386</b>



**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**6. Property, plant and equipment**

	Fixtures, fittings and equipment €	Land and Buildings * €	Total €
<b>Cost</b>			
At 1 January 2022	1,507,336	2,002,916	3,510,252
Additions during the year	44,518	-	44,518
Modification	-	(281,152)	(281,152)
Disposals	(15,794)	-	(15,794)
Foreign exchange translation differences	22,772	47,190	69,962
<b>At 31 December 2022</b>	<b>1,558,832</b>	<b>1,768,954</b>	<b>3,327,786</b>
At 1 January 2023	1,558,832	1,768,954	3,327,786
Additions during the year	118,444	646,089	764,533
Foreign exchange translation differences	(10,478)	(19,668)	(30,146)
<b>At 31 December 2023</b>	<b>1,666,798</b>	<b>2,395,375</b>	<b>4,062,173</b>
<b>Depreciation</b>			
At 1 January 2022	1,283,667	943,700	2,227,367
Charge for the year	92,545	367,468	460,013
Disposals	(9,827)	-	(9,827)
Foreign exchange translation differences	16,568	19,886	36,454
<b>At 31 December 2022</b>	<b>1,382,953</b>	<b>1,331,054</b>	<b>2,714,007</b>
At 1 January 2023	1,382,953	1,331,054	2,714,007
Charge for the year	63,961	245,593	309,554
Foreign exchange translation differences	6,828	(5,250)	1,579
<b>At 31 December 2023</b>	<b>1,453,742</b>	<b>1,571,397</b>	<b>3,025,139</b>
<b>Net book value</b>			
At 1 January 2022	223,669	1,059,216	1,282,885
At 31 December 2022	175,879	437,900	613,779
<b>At 31 December 2023</b>	<b>213,056</b>	<b>823,978</b>	<b>1,037,034</b>

\* Land and Buildings is comprised of Right of Use assets, held under leases.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**7. Trade and other receivables**

	<b>2023</b> <b>Unaudited</b> €	2022 Audited €
<i>Amounts falling due within one year:</i>		
Trade receivables	<b>2,524,369</b>	995,595
Prepaid expenses and other current assets	<b>1,723,146</b>	1,638,690
Research and development tax credit	<b>1,460,531</b>	628,224
Sales tax recoverable	-	79,654
	<b>5,708,046</b>	3,342,163
<i>Amounts falling due after more than one year:</i>		
Research and development tax credit	<b>461,061</b>	639,639
	<b>6,169,107</b>	3,981,802

**8. Trade and other payables (current)**

	<b>2023</b> <b>Unaudited</b> €	2022 Audited €
<i>Amounts falling due within one year:</i>		
Trade payables	<b>1,270,907</b>	1,071,692
Payroll related taxes	<b>2,769,607</b>	151,715
Superannuation / retirement benefit	<b>68,368</b>	44,278
Other payables and accruals	<b>2,404,490</b>	2,469,283
Sales tax payable	<b>77,882</b>	74,281
Deferred income	<b>4,849,639</b>	3,234,186
R&D tax credit – deferred grant income	<b>129,318</b>	99,220
	<b>11,570,211</b>	7,144,655

Included within payroll related taxes due at 31 December 2023 is €2,552,194 (2022: €2,476,858) relating to the Irish Revenue Commissioner Debt Warehousing scheme for the period May 2020 to December 2021. The Group is in discussions with the Irish Revenue Commissioners about a Phased Payment Arrangement. In accordance with the rules of the scheme, the Group had been accruing interest at a rate of 3% on the debt. On 5 February 2024, the Minister for Finance announced that the interest rate applicable to warehoused debt will be reduced to 0%. The interest accrued to 31 December 2023 totaling €75,336 will be reversed in the year ended 31 December 2024.

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**9. Trade and other payables (non-current)**

	<b>2023</b>	2022
	<b>Unaudited</b>	Audited
	€	€
Payroll related taxes	-	2,476,858
Other payables and accruals	<b>247,225</b>	312,779
	<hr/> <b>247,225</b> <hr/>	<hr/> 2,789,637 <hr/>

**10. Share capital**

<b>Authorised Share Capital</b>	<b>2023</b>	2022
	<b>Unaudited</b>	Audited
Ordinary shares		
No. of shares	<b>1,000,000,000</b>	750,000,000
Nominal value	<b>€0.001</b>	€0.001
"B" Ordinary shares		
No. of shares	<b>420,000</b>	420,000
Nominal value	<b>€0.01</b>	€0.01
	<b>€</b>	<b>€</b>
Authorised Ordinary Shares	<b>1,000,000</b>	750,000
Authorised "B" Ordinary Shares	<b>4,200</b>	4,200
	<hr/> <b>1,004,200</b> <hr/>	<hr/> 754,200 <hr/>
Authorised Share Capital		

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**10. Share capital (continued)**

Issued share capital	No of ordinary shares	Par value of units	Share Capital	Share premium	Total
<b>Balance at 1 January 2022</b>	<b>518,477,053</b>	<b>€0.001</b>	<b>518,477</b>	<b>120,071,867</b>	<b>120,590,344</b>
Share issue – 13 Jan 2022	444,444	€0.001	444	-	444
Share issue – 11 Apr 2022	538,989	€0.001	539	-	539
Share issue – 4 May 2022	1,164,757	€0.001	1,165	-	1,165
Share issue – 20 Jun 2022	96,000	€0.001	96	-	96
Share issue – 7 Sept 2022	240,796	€0.001	241	-	241
Share issue – 3 Oct 2022	1,104,107	€0.001	1,104	-	1,104
Share issue – 2 Nov 2022	924,298	€0.001	924	-	924
Exercise of options – 9 Nov 2022	12,000,000	€0.001	12,000	297,458	309,458
<b>Balance at 31 December 2022</b>	<b>534,990,444</b>	<b>€0.001</b>	<b>534,990</b>	<b>120,369,325</b>	<b>120,904,315</b>
Share issue – 2 Mar 2023	552,466	€0.001	552	-	552
Share issue – 2 Aug 2023	111,111,111	€0.001	111,111	12,057,300	12,168,411
Share issue – 3 Aug 2023	457,500	€0.001	458	-	458
Share issue – 31 Aug 2023	15,612,474	€0.001	15,613	1,655,759	1,671,372
Share issue – 4 Sept 2023	3,154,377	€0.001	3,154	-	3,154
Share issue – 21 Sept 2023	1,316,667	€0.001	1,317	-	1,317
Share issue – 12 Nov 2023	106,666	€0.001	107	-	107
Share issue – 17 Nov 2023	2,097,189	€0.001	2,097	-	2,097
Share issue – 27 Nov 2023	2,083,333	€0.001	2,083	-	2,083
<b>Balance at 31 December 2023</b>	<b>671,482,227</b>	<b>€0.001</b>	<b>671,482</b>	<b>134,082,384</b>	<b>134,753,866</b>

**Notes to the Preliminary Final Report**  
for the year ended 31 December 2023

**11. Reconciliation of net cash used in operating activities**

	<b>2023</b>	2022
	<b>Unaudited</b>	Audited
	<b>€</b>	€
<b>Loss for the year</b>	<b>(8,934,571)</b>	(10,869,459)
<i>Non-cash items</i>		
Depreciation	<b>309,554</b>	460,013
Loss on disposal of property, plant and equipment	-	5,967
Amortisation of software and development costs	<b>176,424</b>	213,890
Gain on modification of lease liabilities	-	(62,610)
R&D credit, net	<b>(623,631)</b>	(673,798)
Taxation	<b>49,735</b>	(55,221)
Net finance costs	<b>197,537</b>	104,362
Share based payment expense	<b>2,368,348</b>	2,996,691
Foreign exchange loss	<b>314,247</b>	57,527
<b>Changes in assets and liabilities</b>		
Increase in inventories	<b>(1,013,215)</b>	(541,612)
Increase in trade and other receivables	<b>(1,533,576)</b>	(808,434)
(Increase)/decrease in contract assets	<b>(190,871)</b>	69,431
Increase/(decrease) in deferred income	<b>1,607,216</b>	(79,208)
Increase/(decrease) in trade and other payables	<b>181,389</b>	(228,148)
<b>Cash used in operating activities</b>	<b>(7,091,414)</b>	(9,410,609)
Finance charges paid	<b>(127,455)</b>	(104,932)
Interest received	<b>5,254</b>	570
Research and development tax credit received	-	621,561
Income tax paid	<b>(50,173)</b>	(16,671)
<b>Net cash used in operating activities</b>	<b>(7,263,788)</b>	(8,910,081)



James Fitter  
Chief Executive Officer

Date: 26 February 2024

## Corporate Directory

**Registered office  
and business address**

2<sup>nd</sup> Floor Avoca Court  
Temple Road  
Blackrock  
Co. Dublin  
Ireland

**Independent auditor**

KPMG  
Chartered Accountants  
1 Stokes Place  
St. Stephen's Green  
Dublin 2

**Bankers**

HSBC Bank Limited  
Guildford and Weybridge Commercial Centre  
Edgeborough Road  
Guildford  
Surrey GU12BJ  
United Kingdom

**Solicitors**

A&L Goodbody  
25-28 North Wall Quay  
Dublin 1

Clayton Utz  
Level 15  
1 Bligh Street  
Sydney  
NSW 2000  
Australia

**Company secretary**

Helena D'Arcy

**Registry**

Computershare Investor Services Pty Ltd  
Level 4  
60 Carrington Street  
Sydney  
NSW 2000  
Australia

**Company number**

513842

**ABRN:**

610 611 768

**ASX Code:**

ASX: ONE

**Company Website:**

[www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

For personal use only